Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Third Wave

signed agreement

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, has announced an agreement with 3W Wellness Inc. (“Third Wave”) to help drive brand awareness of the company’s Psychedelics Genetic Test kit, developed and commercialized by wholly-owned subsidiary HaluGen Life Sciences […]

Read More…